GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Heron Therapeutics Inc (NAS:HRTX) » Definitions » Beneish M-Score

Heron Therapeutics (Heron Therapeutics) Beneish M-Score : -3.66 (As of Apr. 29, 2024)


View and export this data going back to 1987. Start your Free Trial

What is Heron Therapeutics Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -3.66 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Heron Therapeutics's Beneish M-Score or its related term are showing as below:

HRTX' s Beneish M-Score Range Over the Past 10 Years
Min: -3.66   Med: -2.68   Max: 20.31
Current: -3.66

During the past 13 years, the highest Beneish M-Score of Heron Therapeutics was 20.31. The lowest was -3.66. And the median was -2.68.


Heron Therapeutics Beneish M-Score Historical Data

The historical data trend for Heron Therapeutics's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Heron Therapeutics Beneish M-Score Chart

Heron Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.79 -2.80 20.31 -2.68 -3.66

Heron Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.68 -2.65 -2.19 -2.73 -3.66

Competitive Comparison of Heron Therapeutics's Beneish M-Score

For the Biotechnology subindustry, Heron Therapeutics's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Heron Therapeutics's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Heron Therapeutics's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Heron Therapeutics's Beneish M-Score falls into.



Heron Therapeutics Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Heron Therapeutics for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.9792+0.528 * 1.0058+0.404 * 0.5835+0.892 * 1.1799+0.115 * 0.8688
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.8243+4.679 * -0.235185-0.327 * 1.2187
=-3.66

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was $60.1 Mil.
Revenue was 34.233 + 31.434 + 31.762 + 29.615 = $127.0 Mil.
Gross Profit was 24.348 + 13.226 + 11.604 + 12.761 = $61.9 Mil.
Total Current Assets was $188.8 Mil.
Total Assets was $222.5 Mil.
Property, Plant and Equipment(Net PPE) was $25.6 Mil.
Depreciation, Depletion and Amortization(DDA) was $2.9 Mil.
Selling, General, & Admin. Expense(SGA) was $116.7 Mil.
Total Current Liabilities was $79.7 Mil.
Long-Term Debt & Capital Lease Obligation was $176.6 Mil.
Net Income was -10.724 + -25.008 + -42.059 + -32.768 = $-110.6 Mil.
Non Operating Income was 0 + -0.079 + 0.344 + 0.295 = $0.6 Mil.
Cash Flow from Operations was 2.455 + -9.179 + -27.165 + -24.9 = $-58.8 Mil.
Total Receivables was $52.0 Mil.
Revenue was 30.028 + 26.557 + 27.63 + 23.457 = $107.7 Mil.
Gross Profit was 17.401 + 11.84 + 11.455 + 12.102 = $52.8 Mil.
Total Current Assets was $205.4 Mil.
Total Assets was $251.0 Mil.
Property, Plant and Equipment(Net PPE) was $29.8 Mil.
Depreciation, Depletion and Amortization(DDA) was $2.9 Mil.
Selling, General, & Admin. Expense(SGA) was $120.0 Mil.
Total Current Liabilities was $82.4 Mil.
Long-Term Debt & Capital Lease Obligation was $154.8 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(60.137 / 127.044) / (52.049 / 107.672)
=0.473356 / 0.483403
=0.9792

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(52.798 / 107.672) / (61.939 / 127.044)
=0.49036 / 0.48754
=1.0058

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (188.774 + 25.604) / 222.506) / (1 - (205.435 + 29.805) / 250.951)
=0.036529 / 0.062606
=0.5835

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=127.044 / 107.672
=1.1799

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(2.889 / (2.889 + 29.805)) / (2.899 / (2.899 + 25.604))
=0.088365 / 0.101709
=0.8688

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(116.657 / 127.044) / (119.95 / 107.672)
=0.918241 / 1.114032
=0.8243

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((176.553 + 79.685) / 222.506) / ((154.783 + 82.355) / 250.951)
=1.1516 / 0.944957
=1.2187

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-110.559 - 0.56 - -58.789) / 222.506
=-0.235185

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Heron Therapeutics has a M-score of -3.66 suggests that the company is unlikely to be a manipulator.


Heron Therapeutics Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Heron Therapeutics's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Heron Therapeutics (Heron Therapeutics) Business Description

Traded in Other Exchanges
Address
4242 Campus Point Court, Suite 200, San Diego, CA, USA, 92121
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of SUSTOL, ZYNRELEF, and CINVANTI. Its pipeline product is HTX-011.
Executives
William P Forbes officer: EVP, Chief Development Officer C/O SALIX PHARMACEUTICALS, LTD., 8510 COLONNADE CENTER DRIVE, RALEIGH NC 27615
Adam Morgan other: See Footnote 2 1055B POWERS PLACE, ALPHARETTA GA 30009
Ira Duarte officer: EVP, Chief Financial Officer 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
Craig A Collard director C/O CORNERSTONE THERAPEUTICS INC., 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
Kevin Kotler director C/O BROADFIN CAPITAL, LLC, 300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022
Velan Capital Master Fund Lp other: See Footnote 2 1055B POWERS PLACE, ALPHARETTA GA 30009
Velan Capital Management Llc other: See Footnote 2 1055B POWERS PLACE, ALPHARETTA GA 30009
Velan Capital Holdings Llc other: See Footnote 2 1055B POWERS PLACE, ALPHARETTA GA 30009
Velan Capital Investment Management Lp other: See Footnote 2 1055B POWERS PLACE, ALPHARETTA GA 30009
David Efraim Rosen other: See Footnote 1 155 EAST 44TH ST., SUITE 1630, NEW YORK NY 10017
Rubric Capital Management Lp other: See Footnote 1 155 EAST 44TH ST, SUITE 1630, NEW YORK NY 10017
Balaji Venkataraman other: See Footnote 2 FIRST HORIZON PHARMACEUTICAL CORP, 660 HEMBREE PKWY STE 106, ROSWELL GA 30076
Kimberly Manhard director C/O HERON THERAPEUTICS, INC, 4242 CAMPUS POINT COURT, SUITE 200, SAN DIEGO CA 92121
Craig A Johnson director C/O PURE BIOSCIENCE, 1725 GILLESPIE WAY, EL CAJON CA 92020
Waage Christian director RECEPTOS, INC., 10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121